Blood-based Biomarker For Alzheimer's Disease Diagnostics Market

Future Market Insights

Key Insight

The blood-based biomarker for alzheimer's disease diagnostics market is projected to grow from USD 160.8 million in 2025 to USD 654.4 million by 2035, at a CAGR of 15.1%. Tau-related markers will dominate with a 37.1% market share, while immunoassays will lead the technology outlook segment with a 53.7% share.

October 01, 2025

Anurag Sharma

250 Pages

Cite this Report

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market

https://www.futuremarketinsights.com/reports/blood-based-biomarker-for-alzheimers-disease-diagnostics-market

License

Buy Now

Summary ToC Companies

Key Players

ALZpath
Abbott
C2N Diagnostics
F. Hoffmann-La Roche Ag
Fujirebio
LabCorp
Lilly USA LLC
Quanterix Corporation
Quest Diagnostics
Siemens

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market

Key Players

Similar Industry Reports